Assessing pharmacological interventions for bone metastases: the need for more patient-centered outcomes

Ford, J.A., Mowatt, G. and Jones, R.J. (2012) Assessing pharmacological interventions for bone metastases: the need for more patient-centered outcomes. Expert Review of Clinical Pharmacology, 5(3), pp. 271-279. (doi: 10.1586/ecp.12.21)

Full text not currently available from Enlighten.

Abstract

Bone metastases are associated with a broad spectrum of clinical sequelae. Pain, reduced mobility, skeletal complications and treatment-related events reduce quality of life. Numerous randomized controlled trials have evaluated pharmacological interventions to treat bone metastases. The primary outcomes used have evolved over the past 25 years; from improvement in pain to time to first skeletal-related event (SRE). In the current definition, a SRE consists of pathological fracture, spinal cord compression or the need for radiotherapy or surgery to the bone. Currently used outcomes can detect small differences between interventions. However, there are several limitations to SRE-related outcomes. In this article we illustrate the evolution of outcomes used in randomized controlled trials, critically appraising current outcomes used and proposing that more patient-centered outcomes are needed.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Jones, Professor Robert
Authors: Ford, J.A., Mowatt, G., and Jones, R.J.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Expert Review of Clinical Pharmacology
ISSN:1751-2433

University Staff: Request a correction | Enlighten Editors: Update this record